| scholarly article | Q13442814 |
| P50 | author | Marco Marra | Q6757610 |
| P2093 | author name string | James T Topham | |
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics | Q73231145 | ||
| Chromosome studies in human leukemia. II. Chronic granulocytic leukemia | Q79034773 | ||
| NCI-MATCH trial pushes cancer umbrella trial paradigm | Q95416330 | ||
| Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors | Q21184033 | ||
| An overview of the NCI precision medicine trials-NCI MATCH and MPACT | Q26786719 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Cancer genes and the pathways they control | Q28275089 | ||
| Discovery and saturation analysis of cancer genes across 21 tumour types | Q28305204 | ||
| Tracking genomic cancer evolution for precision medicine: the lung TRACERx study | Q28655985 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| Advances in understanding cancer genomes through second-generation sequencing | Q30014827 | ||
| Treatment of breast cancer | Q30450984 | ||
| Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials | Q30783484 | ||
| Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial | Q33877385 | ||
| A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer | Q34760642 | ||
| Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide | Q35237895 | ||
| Opportunities and challenges in the development of targeted therapies | Q35723796 | ||
| Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing | Q36256943 | ||
| Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers | Q36851421 | ||
| Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial | Q38581287 | ||
| A rapid RT-PCR based method for the detection of BCR-ABL translocation | Q40727320 | ||
| Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine | Q42204869 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | decision making | Q1331926 |
| P304 | page(s) | e1002189 | |
| P577 | publication date | 2016-12-06 | |
| P1433 | published in | PLOS MEDICINE | Q1686921 |
| P1476 | title | Sequencing Strategies to Guide Decision Making in Cancer Treatment | |
| P478 | volume | 13 |
| Q92602032 | An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies | cites work | P2860 |
Search more.